CVS Health Corporation (CVS): Legal Clarity and Core Strengths Support the Bull Case

CVS Health Corporation (CVS): Legal Clarity and Core Strengths Support the Bull Case Neha Gupta Sun, April 12, 2026 at 2:16 PM EDT 2 min read CVS CVS Health Corporation (NYSE: CVS ) is one of the undervalued large cap stocks to buy . On March 25, UBS analyst Kevin Caliendo reiterated a Buy rating and $97 price target on CVS Health Corporation (NYSE:CVS). CVS Health Corporation (CVS): Legal Clarity and Core Strengths Support the Bull Case Source:pexels Caliendo said that CVS’s proposed settlement with the Federal Trade Commission (FTC) over insulin pricing could lift a major cloud that has been hanging over the stock. The settlement relates to a lawsuit the FTC originally filed in September 2024, in which it accused three of the biggest US pharmacy benefit managers (PBMs) of manipulating insulin pricing in ways that harmed patients and consumers. The PBMs are CVS’s Caremark Rx, LLC, Cigna’s Express Scripts, and OptumRx. On March 23, Caremark and Zinc Health Services, LLC, CVS’s group purchasing organization, jointly filed to withdraw the FTC’s complaints against the company. This came after submission and execution of a proposed consent agreement that resolves all claims against CVS’s subsidiaries. Both parties signed off on the deal, though the specific financial terms have been redacted in the docket. Caliendo noted that if the terms of CVS’s settlement mirror those of Express Scripts’ earlier deal, the market is likely to treat this as “an overhang lifted on the stock.” Put…